Anti-GIVA cPLA2 monoclonal antibody

The Alternative Names of target: GIVA cPLA2,Cytosolic phospholipase A2,cPLA2,Phospholipase A2 group IVA,GURDP,cPLA2,PLA2G4,cPLA2-alpha
Pre-made anti-GIVA cPLA2 monoclonal antibody (mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research.

Target products collectionGo to GIVA cPLA2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T14834-Ab-1/ GM-Tg-hg-T14834-Ab-2 Anti-Human GIVA cPLA2 monoclonal antibody Human
GM-Tg-rg-T14834-Ab-1/ GM-Tg-rg-T14834-Ab-2 Anti-Rat GIVA cPLA2 monoclonal antibody Rat
GM-Tg-mg-T14834-Ab-1/ GM-Tg-mg-T14834-Ab-2 Anti-Mouse GIVA cPLA2 monoclonal antibody Mouse
GM-Tg-cynog-T14834-Ab-1/ GM-Tg-cynog-T14834-Ab-2 Anti-Cynomolgus/Rhesus macaque GIVA cPLA2 monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-T14834-Ab-1/ GM-Tg-felg-T14834-Ab-2 Anti-Feline GIVA cPLA2 monoclonal antibody Feline
GM-Tg-cang-T14834-Ab-1/ GM-Tg-cang-T14834-Ab-2 Anti-Canine GIVA cPLA2 monoclonal antibody Canine
GM-Tg-bovg-T14834-Ab-1/ GM-Tg-bovg-T14834-Ab-2 Anti-Bovine GIVA cPLA2 monoclonal antibody Bovine
GM-Tg-equg-T14834-Ab-1/ GM-Tg-equg-T14834-Ab-2 Anti-Equine GIVA cPLA2 monoclonal antibody Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T14834-Ab-1/ GM-Tg-hg-T14834-Ab-2; GM-Tg-rg-T14834-Ab-1/ GM-Tg-rg-T14834-Ab-2;
GM-Tg-mg-T14834-Ab-1/ GM-Tg-mg-T14834-Ab-2; GM-Tg-cynog-T14834-Ab-1/ GM-Tg-cynog-T14834-Ab-2;
GM-Tg-felg-T14834-Ab-1/ GM-Tg-felg-T14834-Ab-2; GM-Tg-cang-T14834-Ab-1/ GM-Tg-cang-T14834-Ab-2;
GM-Tg-bovg-T14834-Ab-1/ GM-Tg-bovg-T14834-Ab-2; GM-Tg-equg-T14834-Ab-1/ GM-Tg-equg-T14834-Ab-2
Products Name Anti-GIVA cPLA2 monoclonal antibody
Format mab
Target Name GIVA cPLA2
Protein Sub-location Introcelluar Protein
Category of antibody Therapeutics Target
Derivation (species) Mouse
CH1+2+3 Isotype
(Receptor identification) 		IgG
Type of Light Chain (VD-LC) N/A
Expression platform Mammalian Expression
Bioactivity validation Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
Tag Fc
Products description Pre-made anti-GIVA cPLA2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data/case study


    Click to get more Data/Case study about the product.





    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

    Comments


    No comments yet.

    Leave a comment